Envista Holdings Corporation (NYSE:NVST – Get Free Report) shares reached a new 52-week high during trading on Thursday after Barclays raised their price target on the stock from $24.00 to $34.00. Barclays currently has an overweight rating on the stock. Envista traded as high as $30.42 and last traded at $30.1890, with a volume of 3500017 shares changing hands. The stock had previously closed at $30.17.
Several other research analysts have also weighed in on the stock. Evercore reissued an “outperform” rating and set a $32.00 price objective on shares of Envista in a report on Friday, February 6th. UBS Group lifted their price target on Envista from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 3rd. Leerink Partners set a $35.00 target price on Envista and gave the stock an “outperform” rating in a report on Friday, February 6th. Robert W. Baird set a $30.00 price target on Envista in a report on Friday, February 6th. Finally, Evercore ISI set a $32.00 price target on Envista and gave the company an “outperform” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $27.43.
Check Out Our Latest Stock Analysis on NVST
Insider Activity at Envista
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Ariel Investments LLC lifted its stake in shares of Envista by 1.7% in the second quarter. Ariel Investments LLC now owns 12,355,666 shares of the company’s stock worth $241,430,000 after buying an additional 210,921 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Envista by 0.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 9,628,460 shares of the company’s stock worth $209,036,000 after acquiring an additional 90,586 shares during the period. Franklin Resources Inc. lifted its position in Envista by 16.7% during the 2nd quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock worth $175,011,000 after acquiring an additional 1,284,767 shares during the last quarter. Alliancebernstein L.P. lifted its position in Envista by 34.0% during the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after acquiring an additional 1,547,656 shares during the last quarter. Finally, Clarkston Capital Partners LLC boosted its holdings in Envista by 0.4% during the second quarter. Clarkston Capital Partners LLC now owns 4,703,330 shares of the company’s stock valued at $91,903,000 after acquiring an additional 16,583 shares during the period.
Envista Price Performance
The company has a market capitalization of $4.77 billion, a P/E ratio of 103.52, a PEG ratio of 1.97 and a beta of 1.01. The stock’s fifty day simple moving average is $23.71 and its 200-day simple moving average is $21.54. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.38 and a quick ratio of 2.04.
Envista (NYSE:NVST – Get Free Report) last announced its earnings results on Thursday, February 5th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.The business’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, equities analysts forecast that Envista Holdings Corporation will post 1 earnings per share for the current fiscal year.
Envista Company Profile
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Featured Stories
- Five stocks we like better than Envista
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Your Bank Account Is No Longer Safe
- The Next Commodity Crunch (bigger than oil?)
- What a Former CIA Agent Knows About the Coming Collapse
- Silicon Valley insiders hint at 12-month AI warning
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
